RT Journal Article
SR Electronic
T1 Intratumor bacteria is associated with prognosis in clear-cell renal cell carcinoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.29.23300629
DO 10.1101/2023.12.29.23300629
A1 Li, Yuqing
A1 Zhang, Dengwei
A1 Tan, Linyi
A1 Xu, Junyao
A1 Guo, Ting
A1 Sun, Yang
A1 Zhang, Rui
A1 Cheng, Yao
A1 Jiang, Haowen
A1 Zhai, Wei
A1 Li, Yong-xin
A1 Feng, Chenchen
YR 2023
UL http://medrxiv.org/content/early/2023/12/29/2023.12.29.23300629.abstract
AB Background Intratumor bacteria (ITB) plays a role in various cancer types. Its role in clear-cell renal cell carcinoma (ccRCC) remains elusive due to small sample size and inadequate decontamination in relevant studies.Objective To establish common and reproducible ITB-associated biomarkers in ccRCC.Design, setting, and participants This retrospective study comprised seven bulk RNA sequencing datasets from six publicly available cohorts and one in-house Chinese cohort (Renji), one 16S rRNA sequencing dataset from an original Chinese cohort (Huashan), and one publicly available single-cell RNA sequencing dataset. All of these datasets included ccRCC cases.Outcome measurements and statistical analysis Composition was presented by relative abundance. Overall and progression-free survival were primary outcomes profiled by putative ITB load and risk score, respectively. Potential host interaction was exploratorily analyzed using gene set enrichment analysis and Sparse CCA.Results and limitations Nine cohorts encompassing a total of 1049 ccRCC cases and 130 paired normal tissues were initially analyzed and underwent decontamination. Surprisingly, neither diversity nor composition was differentially distributed between normal and cancer tissue. High putative bacterial load was associated with better overall survival. Notably, a 7-genera dichotomized ITB risk score was indicative of overall survival and a 13-genera dichotomized ITB risk score was predictive of progression-free survival, respectively. Actinomyces, Rothia and Bifidobacterium showed a protective role while Exiguobacterium was a risk factor. A limitation is lack of causation analyses.Conclusions ITB exists in ccRCC. High ITB loads and ITB-risk score predicts better ccRCC survival regardless of sequencing tech, sample processing or racial disparity.Patient Summary In this report, we explored the role of intratumor bacteria (ITB) in renal clear-cell carcinoma (ccRCC) in patients with different race and sequencing platforms. Putative ITB load and a 7-genera ITB risk score were associated with overall survival. A 13-genera ITB risk score was predictive of progression-free survival. We conclude that certain ITB features are universally pathogenic to ccRCC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was sponsored in part by the National Natural Science Foundation of China (Grant No. 81874123 and 82273248).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained for all patients and the study was approved by Huashan Institutional Review Board (HIRB2011-009; HIRB2023-908) and Renji Hospital, School of Medicine, Shanghai Jiao Tong University (KY2023-049-B).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes